Ledipasvir-sofosbuvir combination proves effective in subset of patients with chronic hepatitis C

A new study presented today at The International Liver Congress™ 2015 has demonstrated that ledipasvir in combination with sofosbuvir achieves sustained virologic response rates 12 weeks after treatment (SVR12; primary endpoint), of 93 percent and 95 percent in patients chronically infected with hepatitis C virus genotypes 4 or 5, respectively. —> Read More